High-grade gliomas; Glioblastoma; Magnetic resonance Imaging; Diffusion magnetic resonance imaging; Positron emission tomography; Neurology (clinical); General Medicine; Surgery
Résumé :
[en] Although imaging of gliomas has evolved tremendously over the last decades, published techniques and protocols are not always implemented into clinical practice. Furthermore, most of the published literature focuses on specific timepoints in glioma management. This article reviews the current literature on conventional and advanced imaging techniques and chronologically outlines their practical relevance for the clinical management of gliomas throughout the cycle of care. Relevant articles were located through the Pubmed/Medline database and included in this review. Interpretation of conventional and advanced imaging techniques is crucial along the entire process of glioma care, from diagnosis to follow-up. In addition to the described currently existing techniques, we expect deep learning or machine learning approaches to assist each step of glioma management through tumor segmentation, radiogenomics, prognostication, and characterization of pseudoprogression. Thorough knowledge of the specific performance, possibilities, and limitations of each imaging modality is key for their adequate use in glioma management.
REUTER, Gilles ; Centre Hospitalier Universitaire de Liège - CHU > > Service de neurochirurgie
MOISE, Martin ; Centre Hospitalier Universitaire de Liège - CHU > > Service médical de radiodiagnostic
Roll, Wolfgang; Department of Nuclear Medicine, University Hospital of Münster, Münster, Germany
MARTIN, Didier ; Centre Hospitalier Universitaire de Liège - CHU > > Service de neurochirurgie ; Université de Liège - ULiège > Département des sciences cliniques > Neurochirurgie
LOMBARD, Arnaud ; Centre Hospitalier Universitaire de Liège - CHU > > Service de neurochirurgie
Scholtes, Félix ; Université de Liège - ULiège > GIGA > GIGA Neurosciences - Nervous system disorders and therapy ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Neuro-anatomie ; Centre Hospitalier Universitaire de Liège - CHU > > Service de neurochirurgie
Stummer, Walter; Department of Neurosurgery, University Hospital of Münster, Münster, Germany
Molina, Eric; Department of Neurosurgery, University Hospital of Münster, Münster, Germany
Langue du document :
Anglais
Titre :
Conventional and advanced imaging throughout the cycle of care of gliomas
Abbasi AW, Westerlaan HE, Holtman GA, Aden KM, van Laar PJ, van der Hoorn A (2018) Incidence of tumour progression and pseudoprogression in high-grade gliomas: a systematic review and meta-analysis. Clin Neuroradiol 28:401–411. 10.1007/s00062-017-0584-x DOI: 10.1007/s00062-017-0584-x
Al-Okaili RN, Krejza J, Wang S, Woo JH, Melhem ER (2006) Advanced MR imaging techniques in the diagnosis of intraaxial brain tumors in adults. Radiographics 26(Suppl 1):S173–S189. 10.1148/rg.26si065513 DOI: 10.1148/rg.26si065513
Albert NL, Weller M, Suchorska B, Galldiks N, Soffietti R, Kim MM, la Fougere C, Pope W, Law I, Arbizu J, Chamberlain MC, Vogelbaum M, Ellingson BM, Tonn JC (2016) Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro-Oncology 18:1199–1208. 10.1093/neuonc/now058 DOI: 10.1093/neuonc/now058
Alkadhi H, Kollias SS, Crelier GR, Golay X, Hepp-Reymond MC, Valavanis A (2000) Plasticity of the human motor cortex in patients with arteriovenous malformations: a functional MR imaging study. AJNR Am J Neuroradiol 21:1423–1433
Alkhalili K, Zenonos G, Tataryn Z, Amankulor N, Engh J (2018) The utility of early postoperative head computed tomography in brain tumor surgery: a retrospective analysis of 755 cases. World Neurosurg 111:e206–e212. 10.1016/j.wneu.2017.12.038 DOI: 10.1016/j.wneu.2017.12.038
Amdouni EG, B. (2018) Semantic representation of neuroimaging observations: proof of concept based on the VASARI terminology. Paper presented at the International Conference on Knowledge Engineering and Ontology Development, Seville, Spain.
Andronesi OC, Loebel F, Bogner W, Marjanska M, Vander Heiden MG, Iafrate AJ, Dietrich J, Batchelor TT, Gerstner ER, Kaelin WG, Chi AS, Rosen BR, Cahill DP (2016) Treatment response assessment in IDH-mutant glioma patients by noninvasive 3D functional spectroscopic mapping of 2-hydroxyglutarate. Clin Cancer Res 22:1632–1641. 10.1158/1078-0432.CCR-15-0656 DOI: 10.1158/1078-0432.CCR-15-0656
Artzi M, Blumenthal DT, Bokstein F, Nadav G, Liberman G, Aizenstein O, Ben Bashat D (2015) Classification of tumor area using combined DCE and DSC MRI in patients with glioblastoma. J Neuro-Oncol 121:349–357. 10.1007/s11060-014-1639-3 DOI: 10.1007/s11060-014-1639-3
Berberat J, McNamara J, Remonda L, Bodis S, Rogers S (2014) Diffusion tensor imaging for target volume definition in glioblastoma multiforme. Strahlenther Onkol 190:939–943. 10.1007/s00066-014-0676-3 DOI: 10.1007/s00066-014-0676-3
Berghoff AS, Rajky O, Winkler F, Bartsch R, Furtner J, Hainfellner JA, Goodman SL, Weller M, Schittenhelm J, Preusser M (2013) Invasion patterns in brain metastases of solid cancers. Neuro-Oncology 15:1664–1672. 10.1093/neuonc/not112 DOI: 10.1093/neuonc/not112
Berndt M, Lange N, Ryang YM, Meyer B, Zimmer C, Hapfelmeier A, Wantia N, Gempt J, Lummel N (2018) Value of diffusion-weighted Imaging in the diagnosis of postoperative intracranial infections. World Neurosurg 118:e245–e253. 10.1016/j.wneu.2018.06.167 DOI: 10.1016/j.wneu.2018.06.167
Bertrand A, Leclercq D, Martinez-Almoyna L, Girard N, Stahl JP, De-Broucker T (2017) MR imaging of adult acute infectious encephalitis. Med Mal Infect 47:195–205. 10.1016/j.medmal.2017.01.002 DOI: 10.1016/j.medmal.2017.01.002
Bette S, Barz M, Huber T, Straube C, Schmidt-Graf F, Combs SE, Delbridge C, Gerhardt J, Zimmer C, Meyer B, Kirschke JS, Boeckh-Behrens T, Wiestler B, Gempt J (2018) Retrospective analysis of radiological recurrence patterns in glioblastoma, their prognostic value and association to postoperative infarct volume. Sci Rep 8:4561. 10.1038/s41598-018-22697-9 DOI: 10.1038/s41598-018-22697-9
Bette S, Gempt J, Huber T, Boeckh-Behrens T, Ringel F, Meyer B, Zimmer C, Kirschke JS (2016) Patterns and time dependence of unspecific enhancement in postoperative magnetic resonance Imaging after glioblastoma resection. World Neurosurg 90:440–447. 10.1016/j.wneu.2016.03.031 DOI: 10.1016/j.wneu.2016.03.031
Bette S, Wiestler B, Kaesmacher J, Huber T, Gerhardt J, Barz M, Delbridge C, Ryang YM, Ringel F, Zimmer C, Meyer B, Boeckh-Behrens T, Kirschke JS, Gempt J (2016) Infarct volume after glioblastoma surgery as an independent prognostic factor. Oncotarget 7:61945-61954. Doi:10.18632/oncotarget.11482 DOI: 10.18632/oncotarget.11482
Blanc-Durand P, Van Der Gucht A, Schaefer N, Itti E, Prior JO (2018) Automatic lesion detection and segmentation of 18F-FET PET in gliomas: a full 3D U-Net convolutional neural network study. PLoS One 13:e0195798. 10.1371/journal.pone.0195798 DOI: 10.1371/journal.pone.0195798
Blasel S, Zagorcic A, Jurcoane A, Bahr O, Wagner M, Harter PN, Hattingen E (2016) Perfusion MRI in the evaluation of suspected glioblastoma recurrence. J Neuroimaging 26:116–123. 10.1111/jon.12247 DOI: 10.1111/jon.12247
Boxerman JL, Ellingson BM, Jeyapalan S, Elinzano H, Harris RJ, Rogg JM, Pope WB, Safran H (2017) Longitudinal DSC-MRI for distinguishing tumor recurrence from pseudoprogression in patients with a high-grade glioma. Am J Clin Oncol 40:228–234. 10.1097/COC.0000000000000156 DOI: 10.1097/COC.0000000000000156
Brown R, Zlatescu M, Sijben A, Roldan G, Easaw J, Forsyth P, Parney I, Sevick R, Yan E, Demetrick D, Schiff D, Cairncross G, Mitchell R (2008) The use of magnetic resonance imaging to noninvasively detect genetic signatures in oligodendroglioma. Clin Cancer Res 14:2357–2362. 10.1158/1078-0432.CCR-07-1964 DOI: 10.1158/1078-0432.CCR-07-1964
Buchmann N, Klasner B, Gempt J, Bauer JS, Pyka T, Delbridge C, Meyer B, Krause BJ, Ringel F (2016) (18)F-Fluoroethyl-l-thyrosine positron emission tomography to delineate tumor residuals after glioblastoma resection: a comparison with standard postoperative magnetic resonance imaging. World Neurosurg 89:420–426. 10.1016/j.wneu.2016.02.032 DOI: 10.1016/j.wneu.2016.02.032
Carrillo JA, Lai A, Nghiemphu PL, Kim HJ, Phillips HS, Kharbanda S, Moftakhar P, Lalaezari S, Yong W, Ellingson BM, Cloughesy TF, Pope WB (2012) Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma. AJNR Am J Neuroradiol 33:1349–1355. 10.3174/ajnr.A2950 DOI: 10.3174/ajnr.A2950
Cha S, Knopp EA, Johnson G, Wetzel SG, Litt AW, Zagzag D (2002) Intracranial mass lesions: dynamic contrast-enhanced susceptibility-weighted echo-planar perfusion MR imaging. Radiology 223:11–29. 10.1148/radiol.2231010594 DOI: 10.1148/radiol.2231010594
Chan JH, Tsui EY, Chau LF, Chow KY, Chan MS, Yuen MK, Chan TL, Cheng WK, Wong KP (2002) Discrimination of an infected brain tumor from a cerebral abscess by combined MR perfusion and diffusion imaging. Comput Med Imaging Graph 26:19–23. 10.1016/s0895-6111(01)00023-4 DOI: 10.1016/s0895-6111(01)00023-4
Chen YR, Ugiliweneza B, Burton E, Woo SY, Boakye M, Skirboll S (2017) The effect of postoperative infection on survival in patients with glioblastoma. J Neurosurg 127:807–811. 10.3171/2016.8.JNS16836 DOI: 10.3171/2016.8.JNS16836
Choi C, Ganji SK, DeBerardinis RJ, Hatanpaa KJ, Rakheja D, Kovacs Z, Yang XL, Mashimo T, Raisanen JM, Marin-Valencia I, Pascual JM, Madden CJ, Mickey BE, Malloy CR, Bachoo RM, Maher EA (2012) 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat Med 18:624–629. 10.1038/nm.2682 DOI: 10.1038/nm.2682
Chow DS, Qi J, Guo X, Miloushev VZ, Iwamoto FM, Bruce JN, Lassman AB, Schwartz LH, Lignelli A, Zhao B, Filippi CG (2014) Semiautomated volumetric measurement on postcontrast MR imaging for analysis of recurrent and residual disease in glioblastoma multiforme. AJNR Am J Neuroradiol 35:498–503. 10.3174/ajnr.A3724 DOI: 10.3174/ajnr.A3724
Colen R, Foster I, Gatenby R, Giger ME, Gillies R, Gutman D, Heller M, Jain R, Madabhushi A, Madhavan S, Napel S, Rao A, Saltz J, Tatum J, Verhaak R, Whitman G (2014) NCI workshop report: clinical and computational requirements for correlating imaging phenotypes with genomics signatures. Transl Oncol 7:556–569. 10.1016/j.tranon.2014.07.007 DOI: 10.1016/j.tranon.2014.07.007
Comi AM (2011) Presentation, diagnosis, pathophysiology, and treatment of the neurological features of Sturge-Weber syndrome. Neurologist 17:179–184. 10.1097/NRL.0b013e318220c5b6 DOI: 10.1097/NRL.0b013e318220c5b6
Cordova JS, Shu HK, Liang Z, Gurbani SS, Cooper LA, Holder CA, Olson JJ, Kairdolf B, Schreibmann E, Neill SG, Hadjipanayis CG, Shim H (2016) Whole-brain spectroscopic MRI biomarkers identify infiltrating margins in glioblastoma patients. Neuro-Oncology 18:1180–1189. 10.1093/neuonc/now036 DOI: 10.1093/neuonc/now036
De la Garza-Ramos R, Kerezoudis P, Tamargo RJ, Brem H, Huang J, Bydon M (2016) Surgical complications following malignant brain tumor surgery: an analysis of 2002-2011 data. Clin Neurol Neurosurg 140:6–10. 10.1016/j.clineuro.2015.11.005 DOI: 10.1016/j.clineuro.2015.11.005
Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H, Pekmezci M, Rice T, Kosel ML, Smirnov IV, Sarkar G, Caron AA, Kollmeyer TM, Praska CE, Chada AR, Halder C, Hansen HM, McCoy LS, Bracci PM, Marshall R, Zheng S, Reis GF, Pico AR, O'Neill BP, Buckner JC, Giannini C, Huse JT, Perry A, Tihan T, Berger MS, Chang SM, Prados MD, Wiemels J, Wiencke JK, Wrensch MR, Jenkins RB (2015) Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 372:2499–2508. 10.1056/NEJMoa1407279 DOI: 10.1056/NEJMoa1407279
ElBanan MG, Amer AM, Zinn PO, Colen RR (2015) Imaging genomics of glioblastoma: state of the art bridge between genomics and neuroradiology. Neuroimaging Clin N Am 25:141–153. 10.1016/j.nic.2014.09.010 DOI: 10.1016/j.nic.2014.09.010
Ellingson BM, Bendszus M, Boxerman J, Barboriak D, Erickson BJ, Smits M, Nelson SJ, Gerstner E, Alexander B, Goldmacher G, Wick W, Vogelbaum M, Weller M, Galanis E, Kalpathy-Cramer J, Shankar L, Jacobs P, Pope WB, Yang D, Chung C, Knopp MV, Cha S, van den Bent MJ, Chang S, Yung WK, Cloughesy TF, Wen PY, Gilbert MR, Jumpstarting Brain Tumor Drug Development Coalition Imaging Standardization Steering C (2015) Consensus recommendations for a standardized brain tumor imaging protocol in clinical trials. Neuro-Oncology 17:1188–1198. 10.1093/neuonc/nov095 DOI: 10.1093/neuonc/nov095
Ellingson BM, Cloughesy TF, Pope WB, Zaw TM, Phillips H, Lalezari S, Nghiemphu PL, Ibrahim H, Naeini KM, Harris RJ, Lai A (2012) Anatomic localization of O6-methylguanine DNA methyltransferase (MGMT) promoter methylated and unmethylated tumors: a radiographic study in 358 de novo human glioblastomas. Neuroimage 59:908–916. 10.1016/j.neuroimage.2011.09.076 DOI: 10.1016/j.neuroimage.2011.09.076
Ellingson BM, Lai A, Harris RJ, Selfridge JM, Yong WH, Das K, Pope WB, Nghiemphu PL, Vinters HV, Liau LM, Mischel PS, Cloughesy TF (2013) Probabilistic radiographic atlas of glioblastoma phenotypes. AJNR Am J Neuroradiol 34:533–540. 10.3174/ajnr.A3253 DOI: 10.3174/ajnr.A3253
Fleischmann DF, Unterrainer M, Schon R, Corradini S, Maihofer C, Bartenstein P, Belka C, Albert NL, Niyazi M (2020) Margin reduction in radiotherapy for glioblastoma through (18)F-fluoroethyltyrosine PET? - a recurrence pattern analysis. Radiother Oncol 145:49–55. 10.1016/j.radonc.2019.12.005 DOI: 10.1016/j.radonc.2019.12.005
Freyschlag CF, Gruber R, Bauer M, Grams AE, Thome C (2019) Routine postoperative computed tomography is not helpful after elective craniotomy. World Neurosurg 122:e1426–e1431. 10.1016/j.wneu.2018.11.079 DOI: 10.1016/j.wneu.2018.11.079
Fujiwara N, Sakatani K, Katayama Y, Murata Y, Hoshino T, Fukaya C, Yamamoto T (2004) Evoked-cerebral blood oxygenation changes in false-negative activations in BOLD contrast functional MRI of patients with brain tumors. Neuroimage 21:1464–1471. 10.1016/j.neuroimage.2003.10.042 DOI: 10.1016/j.neuroimage.2003.10.042
Fureder LM, Widhalm G, Gatterbauer B, Dieckmann K, Hainfellner JA, Bartsch R, Zielinski CC, Preusser M, Berghoff AS (2018) Brain metastases as first manifestation of advanced cancer: exploratory analysis of 459 patients at a tertiary care center. Clin Exp Metastasis 35:727–738. 10.1007/s10585-018-9947-1 DOI: 10.1007/s10585-018-9947-1
Galldiks N, Dunkl V, Ceccon G, Tscherpel C, Stoffels G, Law I, Henriksen OM, Muhic A, Poulsen HS, Steger J, Bauer EK, Lohmann P, Schmidt M, Shah NJ, Fink GR, Langen KJ (2018) Early treatment response evaluation using FET PET compared to MRI in glioblastoma patients at first progression treated with bevacizumab plus lomustine. Eur J Nucl Med Mol Imaging 45:2377–2386. 10.1007/s00259-018-4082-4 DOI: 10.1007/s00259-018-4082-4
Galldiks N, Law I, Pope WB, Arbizu J, Langen KJ (2017) The use of amino acid PET and conventional MRI for monitoring of brain tumor therapy. Neuroimage Clin 13:386–394. 10.1016/j.nicl.2016.12.020 DOI: 10.1016/j.nicl.2016.12.020
Galldiks N, Stoffels G, Filss C, Rapp M, Blau T, Tscherpel C, Ceccon G, Dunkl V, Weinzierl M, Stoffel M, Sabel M, Fink GR, Shah NJ, Langen KJ (2015) The use of dynamic O-(2-18F-fluoroethyl)-l-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma. Neuro-Oncology 17:1293–1300. 10.1093/neuonc/nov088 DOI: 10.1093/neuonc/nov088
Gempt J, Forschler A, Buchmann N, Pape H, Ryang YM, Krieg SM, Zimmer C, Meyer B, Ringel F (2013) Postoperative ischemic changes following resection of newly diagnosed and recurrent gliomas and their clinical relevance. J Neurosurg 118:801–808. 10.3171/2012.12.JNS12125 DOI: 10.3171/2012.12.JNS12125
Grand S, Passaro G, Ziegler A, Esteve F, Boujet C, Hoffmann D, Rubin C, Segebarth C, Decorps M, Le Bas JF, Remy C (1999) Necrotic tumor versus brain abscess: importance of amino acids detected at 1H MR spectroscopy--initial results. Radiology 213:785–793. 10.1148/radiology.213.3.r99dc10785 DOI: 10.1148/radiology.213.3.r99dc10785
Gregor A, Cull A, Traynor E, Stewart M, Lander F, Love S (1996) Neuropsychometric evaluation of long-term survivors of adult brain tumours: relationship with tumour and treatment parameters. Radiother Oncol 41:55–59 DOI: 10.1016/S0167-8140(96)91782-X
Han Y, Yan LF, Wang XB, Sun YZ, Zhang X, Liu ZC, Nan HY, Hu YC, Yang Y, Zhang J, Yu Y, Sun Q, Tian Q, Hu B, Xiao G, Wang W, Cui GB (2018) Structural and advanced imaging in predicting MGMT promoter methylation of primary glioblastoma: a region of interest based analysis. BMC Cancer 18:215. 10.1186/s12885-018-4114-2 DOI: 10.1186/s12885-018-4114-2
Hartmann M, Heiland S, Harting I, Tronnier VM, Sommer C, Ludwig R, Sartor K (2003) Distinguishing of primary cerebral lymphoma from high-grade glioma with perfusion-weighted magnetic resonance imaging. Neurosci Lett 338:119–122. 10.1016/s0304-3940(02)01367-8 DOI: 10.1016/s0304-3940(02)01367-8
Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003. 10.1056/NEJMoa043331 DOI: 10.1056/NEJMoa043331
Hollon T, Stummer W, Orringer D, Suero Molina E (2019) Surgical adjuncts to increase the extent of resection: intraoperative MRI, fluorescence, and Raman histology. Neurosurg Clin N Am 30:65–74. 10.1016/j.nec.2018.08.012 DOI: 10.1016/j.nec.2018.08.012
Hu LS, Ning S, Eschbacher JM, Baxter LC, Gaw N, Ranjbar S, Plasencia J, Dueck AC, Peng S, Smith KA, Nakaji P, Karis JP, Quarles CC, Wu T, Loftus JC, Jenkins RB, Sicotte H, Kollmeyer TM, O'Neill BP, Elmquist W, Hoxworth JM, Frakes D, Sarkaria J, Swanson KR, Tran NL, Li J, Mitchell JR (2017) Radiogenomics to characterize regional genetic heterogeneity in glioblastoma. Neuro-Oncology 19:128–137. 10.1093/neuonc/now135 DOI: 10.1093/neuonc/now135
Hutterer M, Nowosielski M, Putzer D, Jansen NL, Seiz M, Schocke M, McCoy M, Gobel G, la Fougere C, Virgolini IJ, Trinka E, Jacobs AH, Stockhammer G (2013) [18F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma. Neuro-Oncology 15:341–351. 10.1093/neuonc/nos300 DOI: 10.1093/neuonc/nos300
Ius T, Isola M, Budai R, Pauletto G, Tomasino B, Fadiga L, Skrap M (2012) Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and its impact on overall survival. A single-institution experience in 190 patients: clinical article. J Neurosurg 117:1039–1052. 10.3171/2012.8.JNS12393 DOI: 10.3171/2012.8.JNS12393
Jaber M, Wolfer J, Ewelt C, Holling M, Hasselblatt M, Niederstadt T, Zoubi T, Weckesser M, Stummer W (2016) The value of 5-aminolevulinic acid in low-grade gliomas and high-grade gliomas lacking glioblastoma imaging features: an analysis based on fluorescence, magnetic resonance imaging, 18F-fluoroethyl tyrosine positron emission tomography, and tumor molecular factors. Neurosurgery 78:401–411; discussion 411. doi: https://doi.org/10.1227/NEU.0000000000001020
Jakola AS, Berntsen EM, Christensen P, Gulati S, Unsgard G, Kvistad KA, Solheim O (2014) Surgically acquired deficits and diffusion weighted MRI changes after glioma resection--a matched case-control study with blinded neuroradiological assessment. PLoS One 9:e101805. 10.1371/journal.pone.0101805 DOI: 10.1371/journal.pone.0101805
Jakola AS, Skjulsvik AJ, Myrmel KS, Sjavik K, Unsgard G, Torp SH, Aaberg K, Berg T, Dai HY, Johnsen K, Kloster R, Solheim O (2017) Surgical resection versus watchful waiting in low-grade gliomas. Ann Oncol 28:1942–1948. 10.1093/annonc/mdx230 DOI: 10.1093/annonc/mdx230
Jansen NL, Schwartz C, Graute V, Eigenbrod S, Lutz J, Egensperger R, Popperl G, Kretzschmar HA, Cumming P, Bartenstein P, Tonn JC, Kreth FW, la Fougere C, Thon N (2012) Prediction of oligodendroglial histology and LOH 1p/19q using dynamic [(18)F]FET-PET imaging in intracranial WHO grade II and III gliomas. Neuro-Oncology 14:1473–1480. 10.1093/neuonc/nos259 DOI: 10.1093/neuonc/nos259
Jansen NL, Suchorska B, Wenter V, Eigenbrod S, Schmid-Tannwald C, Zwergal A, Niyazi M, Drexler M, Bartenstein P, Schnell O, Tonn JC, Thon N, Kreth FW, la Fougere C (2014) Dynamic 18F-FET PET in newly diagnosed astrocytic low-grade glioma identifies high-risk patients. J Nucl Med 55:198–203. 10.2967/jnumed.113.122333 DOI: 10.2967/jnumed.113.122333
Jenkinson MD, Smith TS, Joyce KA, Fildes D, Broome J, du Plessis DG, Haylock B, Husband DJ, Warnke PC, Walker C (2006) Cerebral blood volume, genotype and chemosensitivity in oligodendroglial tumours. Neuroradiology 48:703–713. 10.1007/s00234-006-0122-z DOI: 10.1007/s00234-006-0122-z
Johnson DR, Diehn FE, Giannini C, Jenkins RB, Jenkins SM, Parney IF, Kaufmann TJ (2017) Genetically defined oligodendroglioma is characterized by indistinct tumor borders at MRI. AJNR Am J Neuroradiol 38:678–684. 10.3174/ajnr.A5070 DOI: 10.3174/ajnr.A5070
Kaka N, Hafazalla K, Samawi H, Simpkin A, Perry J, Sahgal A, Das S (2019) Progression-free but no overall survival benefit for adult patients with bevacizumab therapy for the treatment of newly diagnosed glioblastoma: a systematic review and meta-analysis. 11. https://doi.org/10.3390/cancers11111723
Kaneko S, Suero Molina E, Ewelt C, Warneke N, Stummer W (2019) Fluorescence-based measurement of real-time kinetics of protoporphyrin IX after 5-aminolevulinic acid administration in human in situ malignant gliomas. Neurosurgery 85:E739–E746. 10.1093/neuros/nyz129 DOI: 10.1093/neuros/nyz129
Kawaguchi T, Sonoda Y, Shibahara I, Saito R, Kanamori M, Kumabe T, Tominaga T (2016) Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion. J Neuro-Oncol 129:505–514. 10.1007/s11060-016-2201-2 DOI: 10.1007/s11060-016-2201-2
Kebir S, Fimmers R, Galldiks N, Schafer N, Mack F, Schaub C, Stuplich M, Niessen M, Tzaridis T, Simon M, Stoffels G, Langen KJ, Scheffler B, Glas M, Herrlinger U (2016) Late pseudoprogression in glioblastoma: diagnostic value of dynamic O-(2-[18F]fluoroethyl)-L-tyrosine PET. Clin Cancer Res 22:2190–2196. 10.1158/1078-0432.CCR-15-1334 DOI: 10.1158/1078-0432.CCR-15-1334
Kebir S, Khurshid Z, Gaertner FC, Essler M, Hattingen E, Fimmers R, Scheffler B, Herrlinger U, Bundschuh RA, Glas M (2017) Unsupervised consensus cluster analysis of [18F]-fluoroethyl-L-tyrosine positron emission tomography identified textural features for the diagnosis of pseudoprogression in high-grade glioma. Oncotarget 8:8294–8304. 10.18632/oncotarget.14166 DOI: 10.18632/oncotarget.14166
Kebir S, Weber M, Lazaridis L, Deuschl C, Schmidt T, Monninghoff C, Keyvani K, Umutlu L, Pierscianek D, Forsting M, Sure U, Stuschke M, Kleinschnitz C, Scheffler B, Colletti PM, Rubello D, Rischpler C, Glas M (2019) Hybrid 11C-MET PET/MRI combined with “machine learning” in glioma diagnosis according to the revised glioma WHO classification 2016. Clin Nucl Med 44:214–220. 10.1097/RLU.0000000000002398 DOI: 10.1097/RLU.0000000000002398
Keil VC, Pintea B, Gielen GH, Greschus S, Fimmers R, Gieseke J, Simon M, Schild HH, Hadizadeh DR (2017) Biopsy targeting with dynamic contrast-enhanced versus standard neuronavigation MRI in glioma: a prospective double-blinded evaluation of selection benefits. J Neuro-Oncol 133:155–163. 10.1007/s11060-017-2424-x DOI: 10.1007/s11060-017-2424-x
Khan MB, Chakraborty S, Boockvar JA (2016) Gross total resection of glioblastoma improves overall survival and progression-free survival compared to subtotal resection or biopsy alone. Neurosurgery 79:N12–N13. 10.1227/01.neu.0000508600.08200.c1 DOI: 10.1227/01.neu.0000508600.08200.c1
Kickingereder P, Bonekamp D, Nowosielski M, Kratz A, Sill M, Burth S, Wick A, Eidel O, Schlemmer HP, Radbruch A, Debus J, Herold-Mende C, Unterberg A, Jones D, Pfister S, Wick W, von Deimling A, Bendszus M, Capper D (2016) Radiogenomics of glioblastoma: machine learning-based classification of molecular characteristics by using multiparametric and multiregional MR Imaging features. Radiology 281:907–918. 10.1148/radiol.2016161382 DOI: 10.1148/radiol.2016161382
Krings T, Reinges MH, Willmes K, Nuerk HC, Meister IG, Gilsbach JM, Thron A (2002) Factors related to the magnitude of T2* MR signal changes during functional imaging. Neuroradiology 44:459–466. 10.1007/s00234-002-0795-x DOI: 10.1007/s00234-002-0795-x
Kunz M, Thon N, Eigenbrod S, Hartmann C, Egensperger R, Herms J, Geisler J, la Fougere C, Lutz J, Linn J, Kreth S, von Deimling A, Tonn JC, Kretzschmar HA, Popperl G, Kreth FW (2011) Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas. Neuro-Oncology 13:307–316. 10.1093/neuonc/noq196 DOI: 10.1093/neuonc/noq196
Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, Lang FF, McCutcheon IE, Hassenbusch SJ, Holland E, Hess K, Michael C, Miller D, Sawaya R (2001) A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95:190–198. 10.3171/jns.2001.95.2.0190 DOI: 10.3171/jns.2001.95.2.0190
Larsen VA, Simonsen HJ, Law I, Larsson HB, Hansen AE (2013) Evaluation of dynamic contrast-enhanced T1-weighted perfusion MRI in the differentiation of tumor recurrence from radiation necrosis. Neuroradiology 55:361–369. 10.1007/s00234-012-1127-4 DOI: 10.1007/s00234-012-1127-4
Law I, Albert NL, Arbizu J, Boellaard R, Drzezga A, Galldiks N, la Fougere C, Langen KJ, Lopci E, Lowe V, McConathy J, Quick HH, Sattler B, Schuster DM, Tonn JC, Weller M (2019) Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [(18)F]FDG: version 1.0. Eur J Nucl Med Mol Imaging 46:540–557. 10.1007/s00259-018-4207-9 DOI: 10.1007/s00259-018-4207-9
Lawrence YR, Li XA, el Naqa I, Hahn CA, Marks LB, Merchant TE, Dicker AP (2010) Radiation dose-volume effects in the brain. Int J Radiat Oncol Biol Phys 76:S20–S27. 10.1016/j.ijrobp.2009.02.091 DOI: 10.1016/j.ijrobp.2009.02.091
Li YM, Suki D, Hess K, Sawaya R (2016) The influence of maximum safe resection of glioblastoma on survival in 1229 patients: can we do better than gross-total resection? J Neurosurg 124:977–988. 10.3171/2015.5.JNS142087 DOI: 10.3171/2015.5.JNS142087
Liu X, Mangla R, Tian W, Qiu X, Li D, Walter KA, Ekholm S, Johnson MD (2017) The preliminary radiogenomics association between MR perfusion imaging parameters and genomic biomarkers, and their predictive performance of overall survival in patients with glioblastoma. J Neuro-Oncol 135:553–560. 10.1007/s11060-017-2602-x DOI: 10.1007/s11060-017-2602-x
Lohmann P, Werner JM, Shah NJ, Fink GR, Langen KJ, Galldiks N (2019) Combined amino acid positron emission tomography and advanced magnetic resonance imaging in glioma patients. Cancers (Basil) 11. https://doi.org/10.3390/cancers11020153
Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803–820. 10.1007/s00401-016-1545-1 DOI: 10.1007/s00401-016-1545-1
Matsui Y, Maruyama T, Nitta M, Saito T, Tsuzuki S, Tamura M, Kusuda K, Fukuya Y, Asano H, Kawamata T, Masamune K, Muragaki Y (2020) Prediction of lower-grade glioma molecular subtypes using deep learning. J Neuro-Oncol 146:321–327. 10.1007/s11060-019-03376-9 DOI: 10.1007/s11060-019-03376-9
Munck Af Rosenschold P, Costa J, Engelholm SA, Lundemann MJ, Law I, Ohlhues L, Engelholm S (2015) Impact of [18F]-fluoro-ethyl-tyrosine PET imaging on target definition for radiation therapy of high-grade glioma. Neuro-Oncology 17:757–763. 10.1093/neuonc/nou316 DOI: 10.1093/neuonc/nou316
Muther M, Koch R, Weckesser M, Sporns P, Schwindt W, Stummer W (2019) 5-Aminolevulinic acid fluorescence-guided resection of 18F-FET-PET positive tumor beyond gadolinium enhancing tumor improves survival in glioblastoma. Neurosurgery 85:E1020–E1029. 10.1093/neuros/nyz199 DOI: 10.1093/neuros/nyz199
Neska-Matuszewska M, Bladowska J, Sasiadek M, Zimny A (2018) Differentiation of glioblastoma multiforme, metastases and primary central nervous system lymphomas using multiparametric perfusion and diffusion MR imaging of a tumor core and a peritumoral zone-searching for a practical approach. PLoS ONE [Electronic Resource] 13:e0191341 DOI: 10.1371/journal.pone.0191341
Nguyen HS, Milbach N, Hurrell SL, Cochran E, Connelly J, Bovi JA, Schultz CJ, Mueller WM, Rand SD, Schmainda KM, LaViolette PS (2016) Progressing bevacizumab-induced diffusion restriction is associated with coagulative necrosis surrounded by viable tumor and decreased overall survival in patients with recurrent glioblastoma. AJNR Am J Neuroradiol 37:2201–2208. 10.3174/ajnr.A4898 DOI: 10.3174/ajnr.A4898
Nicolasjilwan M, Hu Y, Yan C, Meerzaman D, Holder CA, Gutman D, Jain R, Colen R, Rubin DL, Zinn PO, Hwang SN, Raghavan P, Hammoud DA, Scarpace LM, Mikkelsen T, Chen J, Gevaert O, Buetow K, Freymann J, Kirby J, Flanders AE, Wintermark M, Group TGPR (2015) Addition of MR imaging features and genetic biomarkers strengthens glioblastoma survival prediction in TCGA patients. J Neuroradiol 42:212–221. 10.1016/j.neurad.2014.02.006 DOI: 10.1016/j.neurad.2014.02.006
Nimsky C, Ganslandt O, Cerny S, Hastreiter P, Greiner G, Fahlbusch R (2000) Quantification of, visualization of, and compensation for brain shift using intraoperative magnetic resonance imaging. Neurosurgery 47:1070–1079; discussion 1079-1080. doi: https://doi.org/10.1097/00006123-200011000-00008
Niyazi M, Brada M, Chalmers AJ, Combs SE, Erridge SC, Fiorentino A, Grosu AL, Lagerwaard FJ, Minniti G, Mirimanoff RO, Ricardi U, Short SC, Weber DC, Belka C (2016) ESTRO-ACROP guideline “target delineation of glioblastomas”. Radiother Oncol 118:35–42. 10.1016/j.radonc.2015.12.003 DOI: 10.1016/j.radonc.2015.12.003
Okada H, Weller M, Huang R, Finocchiaro G, Gilbert MR, Wick W, Ellingson BM, Hashimoto N, Pollack IF, Brandes AA, Franceschi E, Herold-Mende C, Nayak L, Panigrahy A, Pope WB, Prins R, Sampson JH, Wen PY, Reardon DA (2015) Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol 16:e534–e542. 10.1016/S1470-2045(15)00088-1 DOI: 10.1016/S1470-2045(15)00088-1
Oppenlander ME, Wolf AB, Snyder LA, Bina R, Wilson JR, Coons SW, Ashby LS, Brachman D, Nakaji P, Porter RW, Smith KA, Spetzler RF, Sanai N (2014) An extent of resection threshold for recurrent glioblastoma and its risk for neurological morbidity. J Neurosurg 120:846–853. 10.3171/2013.12.JNS13184 DOI: 10.3171/2013.12.JNS13184
Papp L, Potsch N, Grahovac M, Schmidbauer V, Woehrer A, Preusser M, Mitterhauser M, Kiesel B, Wadsak W, Beyer T, Hacker M, Traub-Weidinger T (2018) Glioma survival prediction with combined analysis of in vivo (11)C-MET PET features, ex vivo features, and patient features by supervised machine learning. J Nucl Med 59:892–899. 10.2967/jnumed.117.202267 DOI: 10.2967/jnumed.117.202267
Paulsson AK, McMullen KP, Peiffer AM, Hinson WH, Kearns WT, Johnson AJ, Lesser GJ, Ellis TL, Tatter SB, Debinski W, Shaw EG, Chan MD (2014) Limited margins using modern radiotherapy techniques does not increase marginal failure rate of glioblastoma. Am J Clin Oncol 37:177–181. 10.1097/COC.0b013e318271ae03 DOI: 10.1097/COC.0b013e318271ae03
Peeken JC, Goldberg T, Pyka T, Bernhofer M, Wiestler B, Kessel KA, Tafti PD, Nusslin F, Braun AE, Zimmer C, Rost B, Combs SE (2019) Combining multimodal imaging and treatment features improves machine learning-based prognostic assessment in patients with glioblastoma multiforme. Cancer Med 8:128–136. 10.1002/cam4.1908 DOI: 10.1002/cam4.1908
Pirotte BJ, Levivier M, Goldman S, Massager N, Wikler D, Dewitte O, Bruneau M, Rorive S, David P, Brotchi J (2009) Positron emission tomography-guided volumetric resection of supratentorial high-grade gliomas: a survival analysis in 66 consecutive patients. Neurosurgery 64:471–481; discussion 481. 10.1227/01.NEU.0000338949.94496.85 DOI: 10.1227/01.NEU.0000338949.94496.85
Pope WB, Chen JH, Dong J, Carlson MR, Perlina A, Cloughesy TF, Liau LM, Mischel PS, Nghiemphu P, Lai A, Nelson SF (2008) Relationship between gene expression and enhancement in glioblastoma multiforme: exploratory DNA microarray analysis. Radiology 249:268–277. 10.1148/radiol.2491072000 DOI: 10.1148/radiol.2491072000
Price SJ, Young AM, Scotton WJ, Ching J, Mohsen LA, Boonzaier NR, Lupson VC, Griffiths JR, McLean MA, Larkin TJ (2016) Multimodal MRI can identify perfusion and metabolic changes in the invasive margin of glioblastomas. J Magn Reson Imaging 43:487–494. 10.1002/jmri.24996 DOI: 10.1002/jmri.24996
Rahman M, Abbatematteo J, De Leo EK, Kubilis PS, Vaziri S, Bova F, Sayour E, Mitchell D, Quinones-Hinojosa A (2017) The effects of new or worsened postoperative neurological deficits on survival of patients with glioblastoma. J Neurosurg 127:123–131. 10.3171/2016.7.JNS16396 DOI: 10.3171/2016.7.JNS16396
Ricci PE (1999) Imaging of adult brain tumors. Neuroimaging Clin N Am 9:651–669
Rios Velazquez E, Meier R, Dunn WD Jr, Alexander B, Wiest R, Bauer S, Gutman DA, Reyes M, Aerts HJ (2015) Fully automatic GBM segmentation in the TCGA-GBM dataset: prognosis and correlation with VASARI features. Sci Rep 5:16822. 10.1038/srep16822 DOI: 10.1038/srep16822
Rizzo S, Botta F, Raimondi S, Origgi D, Fanciullo C, Morganti AG, Bellomi M (2018) Radiomics: the facts and the challenges of image analysis. Eur Radiol Exp 2:36. 10.1186/s41747-018-0068-z DOI: 10.1186/s41747-018-0068-z
Sacko O, Lauwers-Cances V, Brauge D, Sesay M, Brenner A, Roux FE (2011) Awake craniotomy vs surgery under general anesthesia for resection of supratentorial lesions. Neurosurgery 68:1192–1198; discussion 1198-1199. doi: https://doi.org/10.1227/NEU.0b013e31820c02a3
Sanai N, Polley MY, McDermott MW, Parsa AT, Berger MS (2011) An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg 115:3–8. 10.3171/2011.2.JNS10998 DOI: 10.3171/2011.2.JNS10998
Schebesch KM, Proescholdt M, Hohne J, Hohenberger C, Hansen E, Riemenschneider MJ, Ullrich W, Doenitz C, Schlaier J, Lange M, Brawanski A (2013) Sodium fluorescein-guided resection under the YELLOW 560 nm surgical microscope filter in malignant brain tumor surgery--a feasibility study. Acta Neurochir 155:693–699. 10.1007/s00701-013-1643-y DOI: 10.1007/s00701-013-1643-y
Schucht P, Beck J, Abu-Isa J, Andereggen L, Murek M, Seidel K, Stieglitz L, Raabe A (2012) Gross total resection rates in contemporary glioblastoma surgery: results of an institutional protocol combining 5-aminolevulinic acid intraoperative fluorescence imaging and brain mapping. Neurosurgery 71:927–935; discussion 935-926. doi: https://doi.org/10.1227/NEU.0b013e31826d1e6b
Scott JN, Brasher PM, Sevick RJ, Rewcastle NB, Forsyth PA (2002) How often are nonenhancing supratentorial gliomas malignant? A population study. Neurology 59:947–949. 10.1212/wnl.59.6.947 DOI: 10.1212/wnl.59.6.947
Shaver MM, Kohanteb PA, Chiou C, Bardis MD, Chantaduly C, Bota D, Filippi CG, Weinberg B, Grinband J, Chow DS, Chang PD (2019) Optimizing neuro-oncology Imaging: a review of deep learning approaches for glioma imaging. Cancers (Basel) 11. 10.3390/cancers11060829
Silva MA, See AP, Essayed WI, Golby AJ, Tie Y (2018) Challenges and techniques for presurgical brain mapping with functional MRI. Neuroimage Clin 17:794–803. 10.1016/j.nicl.2017.12.008 DOI: 10.1016/j.nicl.2017.12.008
Smith JS, Chang EF, Lamborn KR, Chang SM, Prados MD, Cha S, Tihan T, Vandenberg S, McDermott MW, Berger MS (2008) Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol 26:1338–1345. 10.1200/JCO.2007.13.9337 DOI: 10.1200/JCO.2007.13.9337
Smits M, van den Bent MJ (2017) Imaging correlates of adult glioma genotypes. Radiology 284:316–331. 10.1148/radiol.2017151930 DOI: 10.1148/radiol.2017151930
Sotoudeh H, Shafaat O, Bernstock JD, Brooks MD, Elsayed GA, Chen JA, Szerip P, Chagoya G, Gessler F, Sotoudeh E, Shafaat A, Friedman GK (2019) Artificial intelligence in the management of glioma: era of personalized medicine. Front Oncol 9:768. 10.3389/fonc.2019.00768 DOI: 10.3389/fonc.2019.00768
Stockhammer F, Plotkin M, Amthauer H, van Landeghem FK, Woiciechowsky C (2008) Correlation of F-18-fluoro-ethyl-tyrosin uptake with vascular and cell density in non-contrast-enhancing gliomas. J Neuro-Oncol 88:205–210. 10.1007/s11060-008-9551-3 DOI: 10.1007/s11060-008-9551-3
Stummer W, Meinel T, Ewelt C, Martus P, Jakobs O, Felsberg J, Reifenberger G (2012) Prospective cohort study of radiotherapy with concomitant and adjuvant temozolomide chemotherapy for glioblastoma patients with no or minimal residual enhancing tumor load after surgery. J Neuro-Oncol 108:89–97. 10.1007/s11060-012-0798-3 DOI: 10.1007/s11060-012-0798-3
Stummer W, Reulen HJ, Meinel T, Pichlmeier U, Schumacher W, Tonn JC, Rohde V, Oppel F, Turowski B, Woiciechowsky C, Franz K, Pietsch T, Group AL-GS (2008) Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery 62:564–576; discussion 564-576. 10.1227/01.neu.0000317304.31579.17 DOI: 10.1227/01.neu.0000317304.31579.17
Stummer W, Suero Molina E (2017) Fluorescence imaging/agents in tumor resection. Neurosurg Clin N Am 28:569–583. 10.1016/j.nec.2017.05.009 DOI: 10.1016/j.nec.2017.05.009
Stuplich M, Hadizadeh DR, Kuchelmeister K, Scorzin J, Filss C, Langen KJ, Schafer N, Mack F, Schuller H, Simon M, Glas M, Pietsch T, Urbach H, Herrlinger U (2012) Late and prolonged pseudoprogression in glioblastoma after treatment with lomustine and temozolomide. J Clin Oncol 30:e180–e183. 10.1200/JCO.2011.40.9565 DOI: 10.1200/JCO.2011.40.9565
Suchorska B, Giese A, Biczok A, Unterrainer M, Weller M, Drexler M, Bartenstein P, Schuller U, Tonn JC, Albert NL (2018) Identification of time-to-peak on dynamic 18F-FET-PET as a prognostic marker specifically in IDH1/2 mutant diffuse astrocytoma. Neuro-Oncology 20:279–288. 10.1093/neuonc/nox153 DOI: 10.1093/neuonc/nox153
Suchorska B, Jansen NL, Linn J, Kretzschmar H, Janssen H, Eigenbrod S, Simon M, Popperl G, Kreth FW, la Fougere C, Weller M, Tonn JC, German Glioma N (2015) Biological tumor volume in 18FET-PET before radiochemotherapy correlates with survival in GBM. Neurology 84:710–719. 10.1212/WNL.0000000000001262 DOI: 10.1212/WNL.0000000000001262
Suero Molina E, Schipmann S, Stummer W (2019) Maximizing safe resections: the roles of 5-aminolevulinic acid and intraoperative MR imaging in glioma surgery-review of the literature. Neurosurg Rev 42:197–208. 10.1007/s10143-017-0907-z DOI: 10.1007/s10143-017-0907-z
Suero Molina E, Stummer W (2018) Where and when to cut? Fluorescein guidance for brain stem and spinal cord tumor surgery-technical note. Oper Neurosurg (Hagerstown) 15:325–331. 10.1093/ons/opx269 DOI: 10.1093/ons/opx269
Suero Molina E, Wolfer J, Ewelt C, Ehrhardt A, Brokinkel B, Stummer W (2018) Dual-labeling with 5-aminolevulinic acid and fluorescein for fluorescence-guided resection of high-grade gliomas: technical note. J Neurosurg 128:399–405. 10.3171/2016.11.JNS161072 DOI: 10.3171/2016.11.JNS161072
Tan W, Xiong J, Huang W, Wu J, Zhan S, Geng D (2017) Noninvasively detecting Isocitrate dehydrogenase 1 gene status in astrocytoma by dynamic susceptibility contrast MRI. J Magn Reson Imaging 45:492–499. 10.1002/jmri.25358 DOI: 10.1002/jmri.25358
Teng J, da Hora CC, Kantar RS, Nakano I, Wakimoto H, Batchelor TT, Chiocca EA, Badr CE, Tannous BA (2017) Dissecting inherent intratumor heterogeneity in patient-derived glioblastoma culture models. Neuro-Oncology 19:820–832. 10.1093/neuonc/now253 DOI: 10.1093/neuonc/now253
Valentini LG, Casali C, Chatenoud L, Chiaffarino F, Uberti-Foppa C, Broggi G (2008) Surgical site infections after elective neurosurgery: a survey of 1747 patients. Neurosurgery 62:88–95; discussion 95-86. doi: https://doi.org/10.1227/01.NEU.0000311065.95496.C5
van Dijken BRJ, van Laar PJ, Holtman GA, van der Hoorn A (2017) Diagnostic accuracy of magnetic resonance imaging techniques for treatment response evaluation in patients with high-grade glioma, a systematic review and meta-analysis. Eur Radiol 27:4129–4144. 10.1007/s00330-017-4789-9 DOI: 10.1007/s00330-017-4789-9
Verger A, Stoffels G, Bauer EK, Lohmann P, Blau T, Fink GR, Neumaier B, Shah NJ, Langen KJ, Galldiks N (2018) Static and dynamic (18)F-FET PET for the characterization of gliomas defined by IDH and 1p/19q status. Eur J Nucl Med Mol Imaging 45:443–451. 10.1007/s00259-017-3846-6 DOI: 10.1007/s00259-017-3846-6
Vettermann F, Suchorska B, Unterrainer M, Nelwan D, Forbrig R, Ruf V, Wenter V, Kreth FW, Herms J, Bartenstein P, Tonn JC, Albert NL (2019) Non-invasive prediction of IDH-wildtype genotype in gliomas using dynamic (18)F-FET PET. Eur J Nucl Med Mol Imaging 46:2581–2589. 10.1007/s00259-019-04477-3 DOI: 10.1007/s00259-019-04477-3
Voss M, Franz K, Steinbach JP, Fokas E, Forster MT, Filipski K, Hattingen E, Wagner M, Breuer S (2019) Contrast enhancing spots as a new pattern of late onset pseudoprogression in glioma patients. J Neuro-Oncol 142:161–169. 10.1007/s11060-018-03076-w DOI: 10.1007/s11060-018-03076-w
Wakai S, Yamakawa K, Manaka S, Takakura K (1982) Spontaneous intracranial hemorrhage caused by brain tumor: its incidence and clinical significance. Neurosurgery 10:437–444. 10.1227/00006123-198204000-00004 DOI: 10.1227/00006123-198204000-00004
Wang YY, Wang K, Li SW, Wang JF, Ma J, Jiang T, Dai JP (2015) Patterns of tumor contrast enhancement predict the prognosis of anaplastic Gliomas with IDH1 mutation. AJNR Am J Neuroradiol 36:2023–2029. 10.3174/ajnr.A4407 DOI: 10.3174/ajnr.A4407
Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963–1972. 10.1200/JCO.2009.26.3541 DOI: 10.1200/JCO.2009.26.3541
White ML, Zhang Y, Kirby P, Ryken TC (2005) Can tumor contrast enhancement be used as a criterion for differentiating tumor grades of oligodendrogliomas? AJNR Am J Neuroradiol 26:784–790
Wick W, Chinot OL, Bendszus M, Mason W, Henriksson R, Saran F, Nishikawa R, Revil C, Kerloeguen Y, Cloughesy T (2016) Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma. Neuro-Oncology 18:1434–1441. 10.1093/neuonc/now091 DOI: 10.1093/neuonc/now091
Wick W, Meisner C, Hentschel B, Platten M, Schilling A, Wiestler B, Sabel MC, Koeppen S, Ketter R, Weiler M, Tabatabai G, von Deimling A, Gramatzki D, Westphal M, Schackert G, Loeffler M, Simon M, Reifenberger G, Weller M (2013) Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Neurology 81:1515–1522. 10.1212/WNL.0b013e3182a95680 DOI: 10.1212/WNL.0b013e3182a95680
Wijnenga MMJ, French PJ, Dubbink HJ, Dinjens WNM, Atmodimedjo PN, Kros JM, Smits M, Gahrmann R, Rutten GJ, Verheul JB, Fleischeuer R, Dirven CMF, Vincent A, van den Bent MJ (2018) The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis. Neuro-Oncology 20:103–112. 10.1093/neuonc/nox176 DOI: 10.1093/neuonc/nox176
Willems PW, van der Sprenkel JW, Tulleken CA, Viergever MA, Taphoorn MJ (2006) Neuronavigation and surgery of intracerebral tumours. J Neurol 253:1123–1136. 10.1007/s00415-006-0158-3 DOI: 10.1007/s00415-006-0158-3
